Supported by:  Labcorp
NIS4® is a blood-based test designed to effectively identify patients with at-risk metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). The more recently developed NIS2+™ is an optimized version of NIS4® that was

Supported by: Intercept Pharmaceuticals, Inc.
Join us for an informative presentation that discusses taking treatment for Primary Biliary Cholangitis (PBC) a step further. Learn about an approved therapy for patients with PBC.
Presenters:
Kris Kowdley,

Supported by: Alnylam Pharmaceuticals
AHP is a rare, genetic disease characterized by debilitating, potentially life-threatening attacks of which the cardinal symptom is severe, diffuse abdominal pain. This presentation will provide a disease overview an

Supported by:  Ipsen 
In primary biliary cholangitis, it is important to look beyond the liver to make meaningful improvements for patients, so how can we optimize regular disease monitoring alongside the impact of symptoms on patients’ lives? Join us to

Supported by: Novo Nordisk
Join us as we review the pathophysiology of metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH, non-alcoholic steatohepatitis), including the impact of underlying metabolic comorbidities. We will als

Supported by:  Perspectum
In this session we will introduce cT1, a well-established biomarker in liver disease derived from MRI technology. cT1 has played a pivotal role in numerous clinical trials focused on Steatotic Liver Disease, proving its effectiv

Supported by: Genentech, A Member of the Roche Group
This program will provide an overview of HCC disease and staging, IMbrave150 including the clinical trial design, patient characteristics, pivotal efficacy and safety data, and exploratory subgroup ana

Supported by: Albireo Pharma, Inc., an Ipsen Company
This presentation will focus on two rare, genetic cholestatic liver diseases: Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC). Drs. Mohammad (Vanderbilt University) an

Supported by: Madrigal Pharmaceuticals
This session will explore several emerging concepts in NASH including: (1) epidemiology and comorbidities, (2) pathophysiology and the role of lipotoxicity in the liver, (3) morbidity and mortality, (4) patient iden